Alteon Announces July 17, 2003 Conference Call to Review Initial Results From the Phase 2B Sapphire and Silver Trials of ALT-711 For Systolic Hypertension
Tuesday July 15, 3:57 pm ET
- Conference Call to be Webcast -
RAMSEY, N.J., July 15 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX: ALT - News) will hold a conference call at 8:30 a.m. (ET) on Thursday, July 17, 2003, following the announcement of initial trial results from the Phase 2b SAPPHIRE and SILVER trials with Alteon's lead compound ALT-711 for systolic hypertension. Kenneth I. Moch, President and CEO will host the call and will be joined by Alteon management. Following the management presentation and comments, there will be a question and answer period.
ADVERTISEMENT
The call-in telephone number for the conference call will be 1-800-838-4403. International participants may call 1-973-317-5319. Participants should call approximately 5-10 minutes before 8:30 a.m. In addition, the conference call will be accessible through a webcast on the company website, www.alteon.com at the Investor Relations section, and a digital rebroadcast will be available through July 24, 2003 by dialing 1-800-428-6051, passcode 301228 for domestic callers and 1-973-709-2089, passcode 301228 for international callers.
About Alteon
Alteon is developing several new classes of drugs that reverse or slow down diseases of aging and complications of diabetes. These compounds have an impact on a fundamental pathological process caused by protein-glucose complexes called Advanced Glycation End-products (A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss of flexibility and function in body tissues, organs and vessels and have been shown to be a causative factor in many age-related diseases and diabetic complications. Alteon is initially developing therapies for cardiovascular and kidney diseases in older or diabetic individuals.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, those relating to technology and product development (including the possibility that early clinical trial results may not be predictive of results that will be obtained in large-scale testing or that any clinical trials will not demonstrate sufficient safety and efficacy to obtain requisite approvals or will not result in marketable products), regulatory approval processes, intellectual property rights and litigation, competitive products, ability to obtain financing, and other risks identified in Alteon's filings with the Securities and Exchange Commission. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Alteon undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
